PAS
ACAD icon

Point72 Asia (Singapore)’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 Asia (Singapore)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,726
Closed -$80.4K – 867
2025
Q2 		$80.4K Buy
3,726
+805
+28% +$15K 0.01% 511
2025
Q1 		$48.5K Sell
2,921
-14,053
-83% -$255K 0.01% 576
2024
Q4 		$311K Buy
+16,974
New +$274K 0.08% 183
2024
Q3 		– Sell
-4,538
Closed -$73.7K – 923
2024
Q2 		$73.7K Sell
4,538
-11,980
-73% -$193K 0.02% 555
2024
Q1 		$305K Buy
+16,518
New +$409K 0.08% 276

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Point72 Asia (Singapore)'s ACAD Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 3,726 shares — an estimated $80.4K sold.

Point72 Asia (Singapore) first reported a position in ACAD in Q1 2024 and held it in 5 quarters. The position peaked at $311K in Q4 2024. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Point72 Asia (Singapore) reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 3,726 Acadia Pharmaceuticals shares in Q3 2025, an estimated $80.4K.
  • Point72 Asia (Singapore) first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Point72 Asia (Singapore)'s Acadia Pharmaceuticals position peaked at $311K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.